A significant aspect of Parkinson's disease is the decline in dopamine levels within the brain. This vital chemical messenger is essential for movement, memory, mood, and various critical functions. As the brain loses its dopamine-producing cells, it becomes increasingly difficult to manage movement, resulting in symptoms like tremors, muscle rigidity, and reduced motion.
Exploring a Novel Stem Cell Method
Researchers at Keck Medicine of USC are embarking on an exciting new approach through an initial phase clinical trial. This investigation is assessing the safety and efficacy of specially prepared stem cells implanted into the brain to replace damaged cells and rejuvenate dopamine production.
"Restoring normal dopamine levels in the brain could potentially slow the progression of Parkinson's disease and enhance motor functions," stated Brian Lee, MD, PhD, a neurosurgeon at Keck Medicine and the principal investigator of the study.
Distinct Features of the Stem Cells
The treatment employs a cutting-edge type of laboratory-generated stem cell known as induced pluripotent stem cells (iPSCs). Unlike embryonic stem cells, iPSCs are derived from adult cells, such as skin or blood, and are reprogrammed into a versatile state that enables them to transform into various cell types.
"We believe these iPSCs can effectively mature into dopamine-producing brain cells, providing a promising opportunity to kickstart the brain's dopamine production," remarked Xenos Mason, MD, a neurologist at Keck Medicine who specializes in Parkinson's disease and serves as co-principal investigator of the study.
Procedure Overview
During the surgical procedure, Lee creates a small opening in the skull to access the brain. Utilizing magnetic resonance imaging (MRI) for precision, the stem cells are meticulously implanted into the basal ganglia, a brain area crucial for movement control.
Post-surgery, patients will be closely monitored for 12 to 15 months. Physicians will observe changes in Parkinson's symptoms and watch for possible side effects, such as dyskinesia--excessive movements--or infections. Long-term follow-up will extend up to five years to evaluate safety and outcomes over time.
"Our ultimate aim is to develop a technique that can restore patients' motor functions and significantly improve their quality of life," Lee expressed.
Clinical Trial Details and Oversight
Keck Medicine is one of three locations in the United States participating in this clinical trial, which includes 12 individuals diagnosed with moderate to moderate-severe Parkinson's disease.
This announcement serves to inform about Keck Medicine's research initiatives and does not seek participants.
The stem cell therapy, referred to as RNDP-001, is produced by Kenai Therapeutics, a biotechnology firm dedicated to creating treatments for neurological disorders. The U.S. Food & Drug Administration has granted fast-track designation to the Phase 1 REPLACE™ clinical trial, facilitating an accelerated development and review process.
Disclosure: Mason has previously received an honorarium from Kenai Therapeutics.
